Asia
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
Sanofi said the analysis showed more cases of severe disease could occur following vaccination in patients who had not been previously infected by the dengue virus.
Zhenxing Biopharma raised $322M by selling a 19% share of the company to Kaisa Group Holdings.
Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.
Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.
On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.
Aspen Pharmacare Holdings, a South African generic drug company, plans to establish partnerships to build its China drug portfolio, according to management.
Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.
The funding was led by China Reform Holdings and joined by ChinaEquity Group and several unnamed investors.
Immunochina raised $7.5M to support clinical trials of its CAR-T product for lymphoma.
PRESS RELEASES